Gelteq Limited (NASDAQ:GELS) Short Interest Update

Posted by Mitch Edgeman on May 18th, 2026

Gelteq Limited (NASDAQ:GELS – Get Free Report) was the target of a significant decrease in short interest in April. As of April 30th, there was short interest totaling 37,312 shares, a decrease of 34.3% from the April 15th total of 56,786 shares. Currently, 0.3% of the shares of the stock are short sold. Based on an average daily volume of 12,987 shares, the short-interest ratio is presently 2.9 days.

Gelteq Stock Performance

GELS stock opened at $0.44 on Monday. The business has a 50 day simple moving average of $0.67 and a 200-day simple moving average of $0.85. Gelteq has a 1 year low of $0.39 and a 1 year high of $3.51.

Institutional Investors Weigh In On Gelteq

A hedge fund recently bought a new stake in Gelteq stock. Susquehanna International Group LLP purchased a new stake in Gelteq Limited (NASDAQ:GELS – Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 41,550 shares of the company’s stock, valued at approximately $57,000. Susquehanna International Group LLP owned approximately 0.44% of Gelteq at the end of the most recent reporting period.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered Gelteq from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, May 7th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Gelteq has an average rating of “Sell”.

View Our Latest Analysis on GELS

About Gelteq

(Get Free Report)

Gelteq Inc is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc is based in NEW YORK.